Alice Nennecke

Dr. Alice Nennecke

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AKAlexander Katalinic
Alexander Katalinic
Marco HalberMarco Halber
Marco Halber
MMMartin Meyer
Martin Meyer
MPMaren Pflüger
Maren Pflüger
AEAndrea Eberle
Andrea Eberle
RPRon Pritzkuleit
Ron Pritzkuleit
Introduction: In 2013, a new federal law obligated all German federal states to collect additional clinical data in population-based cancer registries as an active tool for monitoring and improving the quality of cancer care, increasing transparency and promoting health research. Now, 10 years later, the current status of the expanded cancer registration is presented, including current figures on cancer in Germany. Methods: Reporting of cancer is mandatory for physicians, and about 5 to 10 reports from different healthcare providers are expected for each case. A uniform national dataset of about 130 items is used, and reports are usually sent electronically to the registry. We used the most recent data available from cancer registries up to the year of diagnosis in 2019. We calculated incidence rates and 5-year relative survival (5YRS) for common cancers. Data on clinical outcomes and benchmarking based on quality indicators (QIs) from guidelines were provided by the Cancer Registry Schleswig-Holstein (CR SH). Results: All federal state cancer registries met most of the previously defined national eligibility criteria. Approximately 505,000 cancer cases were registered in 2019, with breast, prostate, colorectal and lung cancer being the most common cancers. The age-standardised cancer incidence has slightly decreased during the last decade. and spatial heterogeneity can be observed within Germany. 5YRS for all cancers was 67% and 63% for women and men, respectively. Therapy data for rectal cancer in 2019–2021 from the CR SH are shown as an example: 69% of the registered patients underwent surgery, mostly with curative intent (84%) and tumour-free resection (91%). Radiotherapy was given to 33% of the patients, and chemotherapy was given to 40%. Three selected QIs showed differences between involved healthcare providers. Discussion: The implementation of population-based clinical cancer registration can be considered a success. Comprehensive recording of diagnosis, treatment and disease progression and the use of registry data for quality assurance, benchmarking and feedback have been implemented.

1 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DDDaniela Doege
Daniela Doege
MTMelissa Thong
Melissa Thong
LWLinda Weißer
Linda Weißer
LKLena Koch-Gallenkamp
Lena Koch-Gallenkamp
LJLina Jansen
Lina Jansen
VAVolker Arndt
Volker Arndt
(1) Background: Little is known about the health-related quality of life (HRQoL) in very long-term cancer survivors (VLTCS) 10 and more years post-diagnosis. The objective was to compare cancer survivors’ HRQoL 14–24 years post-diagnosis with that of same-aged non-cancer controls, stratified by age, sex, and disease status (disease-free vs. stage IV, recurrence, metastasis, or second cancer). (2) Methods: We recruited 2704 very long-term survivors of breast, colorectal and prostate cancer, and 1765 controls in German multi-regional population-based studies. The HRQoL was assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Differences in the HRQoL were estimated with multiple regression, controlling for age, sex (where appropriate), and education. (3) Results: The overall global health status/quality of life of VLTCS more than a decade after diagnosis was slightly higher than that of population controls of the same age, but more symptoms and lower functioning were reported. Differences were small but statistically significant. Results differed by age, sex, and disease status. (4) Conclusions: The findings point out the need for a comprehensive survivorship care program in order to monitor and treat potential late and long-term effects after the diagnosis and treatment of cancer. Survivorship care should be risk-adapted to survivors’ needs according to sociodemographic and clinical factors.

15 July 2025 in British Journal of Cancer
Verified
Journal Article
Open access
MTMelissa Thong
Melissa Thong
DDDaniela Doege
Daniela Doege
LKLena Koch-Gallenkamp
Lena Koch-Gallenkamp
HBHeike Bertram
Heike Bertram
AEAndrea Eberle
Andrea Eberle
VAVolker Arndt
Volker Arndt
Background: We compared fatigue severity in breast, prostate or colorectal cancer survivors 5–16 years post-diagnosis with cancer-free controls, and examined factors associated with fatigue and its association with all-cause mortality in survivors. Methods: Participants of the CAncEr Survivorship - A multi-Regional (CAESAR) study completed the Fatigue Assessment Questionnaire (FAQ) between 2009 and 2011. The FAQ assesses affective, cognitive, and physical fatigue, and sleep problems. We derived the odds of fatigue using logistic regression with the 75th percentile of population norms as the cut-off. All-cause mortality (up to end 2021) was estimated using Cox regression models. Results: The sample comprised 6057 survivors, of whom approximately one-third reported affective, cognitive, or physical fatigue. Demographic (age, relationship), clinical (chemotherapy), comorbidity (depression), lifestyle, and psychological factors were associated with higher odds of fatigue symptoms and total fatigue. Fatigue symptoms, predominantly physical fatigue, were strongly associated with mortality (unadjusted hazard ratios (HRs) ranged from 1.48 to 2.40). The HRs were attenuated after adjustment for comorbidities and depressive symptoms, although affective and physical fatigue remained independent risk factors for mortality. Conclusions: Demographic, clinical, comorbidity, lifestyle, and psychological factors were associated with fatigue in long-term survivors. Fatigued survivors have a higher mortality risk. Lowering the burden of fatigue by a comprehensive approach might result in better survival.

14 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
MTMelissa Thong
Melissa Thong
DDDaniela Doege
Daniela Doege
LWLinda Weißer
Linda Weißer
LKLena Koch-Gallenkamp
Lena Koch-Gallenkamp
LJLina Jansen
Lina Jansen
VAVolker Arndt
Volker Arndt
(1) Background: The health-related quality of life (HRQOL) of colorectal cancer (CRC) survivors >10 years post-diagnosis is understudied. We aimed to compare the HRQOL of CRC survivors 14–24 years post-diagnosis to that of age- and sex-matched non-cancer controls, stratified by demographic and clinical factors. (2) Methods: We used data from 506 long-term CRC survivors and 1489 controls recruited from German population-based multi-regional studies. HRQOL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (EORTC QLQ-C30) questionnaire. We estimated differences in the HRQOL of CRC survivors and controls with multiple regression, adjusted for age at survey, sex, and education, where appropriate. (3) Results: CRC survivors reported poorer social functioning but better health status/QOL than controls. CRC survivors, in general, had higher levels of symptom burden, and in particular diarrhea and constipation, regardless of demographic or clinical factors. In stratified analyses, HRQOL differed by age, sex, cancer type, and having a permanent stoma. (4) Conclusions: Although CRC survivors may have a comparable health status/QOL to controls 14–24 years after diagnosis, they still live with persistent bowel dysfunction that can negatively impact aspects of functioning. Healthcare providers should provide timely and adapted follow-up care to ameliorate potential long-term suffering.

11 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JCJasmin Carus
Jasmin Carus
LTLeona Trübe
Leona Trübe
PSPhilip Szczepanski
Philip Szczepanski
SNSylvia Nürnberg
Sylvia Nürnberg
HHHanna Hees
Hanna Hees
CGChristopher Gundler
Christopher Gundler
In their joint effort against cancer, all involved parties within the German healthcare system are obligated to report diagnostics, treatments, progression, and follow-up information for tumor patients to the respective cancer registries. Given the federal structure of Germany, the oncological basis dataset (oBDS) operates as the legally required national standard for oncological reporting. Unfortunately, the usage of various documentation software solutions leads to semantic and technical heterogeneity of the data, complicating the establishment of research networks and collective data analysis. Within this feasibility study, we evaluated the transferability of all oBDS characteristics to the standardized vocabularies, a metadata repository of the observational medical outcomes partnership (OMOP) common data model (CDM). A total of 17,844 oBDS expressions were mapped automatically or manually to standardized concepts of the OMOP CDM. In a second step, we converted real patient data retrieved from the Hamburg Cancer Registry to the new terminologies. Given our pipeline, we transformed 1773.373 cancer-related data elements to the OMOP CDM. The mapping of the oBDS to the standardized vocabularies of the OMOP CDM promotes the semantic interoperability of oncological data in Germany. Moreover, it allows the participation in network studies of the observational health data sciences and informatics under the usage of federated analysis beyond the level of individual countries.

1 July 2021 in Cancer
Verified
Journal Article
Open access
PDF file
ZLZhunzhun Liu
Zhunzhun Liu
DDDaniela Doege
Daniela Doege
MTMelissa Thong
Melissa Thong
LKLena Koch‐Gallenkamp
Lena Koch‐Gallenkamp
HBHeike Bertram
Heike Bertram
VAVolker Arndt
Volker Arndt
Background: The objective of this study was to ascertain long‐term cancer survivors' (LTCS') appraisal of medical care and how these perceptions may influence their health and well‐being, including benefit finding (BF) and posttraumatic growth (PTG).Methods: In total, 6952 LTCS from a multiregional population‐based study in Germany completed the Benefit Finding Scale, the Posttraumatic Growth Inventory, the Questionnaire on Stress in Cancer, and self‐designed questions on cognitive appraisal of medical care. The authors explored the mediating role of distress between medical care appraisal and BF and PTG and the possible moderation of time since diagnosis in this relationship.RESULTS: LTCS' medical care appraisals (“no unresolved/untreated symptoms,” “satisfaction with cancer care,” and “satisfaction with care for other diseases”) were positively associated with BF. PTG was positively associated with “no unresolved/untreated symptoms” and negatively associated with “satisfaction with care for other diseases.” Cancer distress partially mediated the associations between appraisals of medical care and BF, between “no unresolved/untreated symptoms” and PTG and between “satisfaction with care for other diseases” and PTG; whereas it totally mediated the association between “satisfaction with cancer care” and PTG. Time was a significant moderator in the model; the negative indirect effect of cognitive appraisal on BF and PTG through cancer distress weakened with longer time since diagnosis.Conclusions: Cancer survivors' medical care appraisal is associated with their perceptions of BF and PTG through distress. Therefore, distress screening could be part of the regular workup to identify distressed cancer survivors who are not satisfied with medical care; these survivors may benefit from interventions to reduce distress and increase BF and PTG.